Precision Biologics will present affinity maturation and characterization of a novel core 2 O-glycan epitope targeting anti-human carcinoma mAb PB-223 at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting on November 7-8, 2024
BETHESDA, Md., Nov. 6, 2024 /PRNewswire/ — Precision Biologics, Inc. reports that affinity maturation and characterization of its novel anti-core 2 O-glycan monoclonal antibody PB-223, will be presented in a poster at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting on November 7-8, 2024, George R. Brown Convention Center, Houston, Texas, USA, Poster title: Affinity Maturation and Characterization of a Novel O-glycan Epitope Targeting
Anti-Human Carcinoma Monoclonal Antibody (mAb) PB-223
Presentation of the poster will be made in person on the following dates and locations:
BACKGROUND:
STUDY PRESENTED AT SITC 2024:
Findings from this study suggest that PB-223 has a strong binding affinity for human cancers expressing core 2 O-glycans and that PB-223 may be a potential candidate for the development of antibody-drug conjugates (ADC) for treatment of various human carcinomas.
The PDF of the poster will be available starting from November 5, 2024, at the following link: https://precision-biologics.com/wp-content/uploads/SITC-2024-POSTER-36X72-inches-final.pdf
View original content to download multimedia:https://www.prnewswire.com/news-releases/precision-biologics-to-announce-development-of-new-monoclonal-antibody-mab-pb-223-at-sitc-houston-tx-november-7-8-2024-302296763.html
SOURCE Precision Biologics
